AVLN — Avalyn Pharma Inc. Common Stock stock price, charts and financials

Latest market price

31.52

-1.91-5.71%

Overview Short InterestFilings

AVLNQT57Avalyn Pharma Inc. Common Stock·NASDAQ

Overview Short InterestFilings

31.52-5.71%

News

Down 5.7% — Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RAPP-3.58%$40.45 GHRS-1.60%$28.26 MESO+1.75%$15.13 ZYME-3.31%$26.57 AGIO-1.61%$33.07 ZBIO-1.47%$31.50 RXRX+8.19%$3.83 GPCR-0.28%$35.00

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	44.33M	Perf Week	-6.11%

Market Cap	1.40B	Forward P/E	-	EPS next Y	-2.94	Insider Trans	-	Shs Float	14.45M	Perf Month	-19.12%

Enterprise Value	1.15B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	4.35%	Perf Quarter	0.22%

Income	-55.76M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	6.10	Perf Half Y	-

Sales	0.00	P/B	3.51	EPS next Y	5.61%	ROA	-13.12%	Short Interest	1.93M	Perf YTD	21.23%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-83.23%	52W High	40.17 -21.53%	Perf Year	-

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-14.25%	52W Low	24.15 30.52%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	7.96% 6.07%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	2.32	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	33.10	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	38.22	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	33.10	EPS Q/Q	95.51%	SMA20	-11.41%	Beta	-0.12	Target Price	60.00

Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-4.89%	Rel Volume	2.27	Prev Close	33.43

Employees	55	LT Debt/Eq	-0.00	Earnings	Sep 02	SMA200	1.51%	Avg Volume	293.09K	Price	31.52

IPO Date	Apr 30, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-26.18% -	Net Debt/EBITDA	4.27	Volume	664,783	Change	-5.71%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-13-26	Reiterated	Morgan Stanley	Overweight	$53 → $57
May-26-26	Initiated	Evercore ISI	Outperform	$51
May-26-26	Initiated	Morgan Stanley	Overweight	$53
May-25-26	Initiated	Jefferies	Buy	$52
May-25-26	Initiated	Guggenheim	Buy	$80

Latest News· Times ET

Sep-16-26

Sep-16-2612:01PM

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directorsglobenewswire.com

Sep-14-26

Sep-14-2612:41PM

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha

Sep-08-26

Sep-08-2604:00AM

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosisglobenewswire.com

04:00AM

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferenceglobenewswire.com

Aug-24-26

Aug-24-2612:01PM

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026globenewswire.com

Aug-13-26

Aug-13-2606:16AM

Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57Benzinga

Aug-12-26

Aug-12-2604:13AM

Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) EstimateBenzinga

04:00AM

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlightsglobenewswire.com

Company

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		0
Gross Profit		0
Selling, General and Administrative Excl. Other		15
Research and Development		77
Other Operating Expense		-1
Operating Income		-91
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		6
Net Income Before Taxes		-85
Income Taxes		0
Consolidated Net Income		-85
Net Income From Continuing Operations		-85
Net Income		-85
EPS (Recurring)		-2.04
EPS (Basic, Before Extraordinaries)		-2.04
EPS (Diluted)		-2.04
EBITDA		-91
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		42
Market Capitalization		—
Operating Lease Expense		—

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.